sur Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Releases Q3 2026 Financial Results
Jaguar Health, Inc., based in San Francisco, has announced its consolidated financial results for the third quarter of 2026. The company's license and grant revenue saw a significant increase, attributed to a U.S. commercial licensing agreement with Woodward Specialty, LLC for Mytesi® and Canalevia®-CA1. However, total net revenue from prescription products decreased by 81.9% compared to the previous year, with net revenue at $0.5 million. This shift aligns with Jaguar's strategic focus on developing a powder-for-oral-solution formulation of crofelemer for rare diseases.
Operational costs showed a decline, reflecting a $1.2 million decrease in loss from operations. Net loss also improved, decreasing by $3.8 million. The company's decision to focus on research and development and reduce operational expenses has impacted their financial standing positively. Despite lower revenue, the reduction in costs offered stability amid strategic transitions.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.